Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29735170 | 0.78 | NPC1 (0.57) | NPC1RAB9AMITFPKMTDP1 | |
| SCHEMBL10940866 | 0.78 | NPC1 (0.57) | NPC1RAB9AMITFPKMTDP1 | |
| SCHEMBL11611242 | 0.78 | NPC1 (0.57) | NPC1RAB9AMITFPKMTDP1 | |
| SCHEMBL6216387 | 0.77 | NPC1 (0.64) | NPC1RAB9AMITFPKMTDP1 | |
| SCHEMBL3625688 | 0.76 | RECQL (0.56) | NPC1RAB9APKMKMT2ASMN1; SMN2 | |
| SCHEMBL13799918 | 0.75 | RAB9A (0.58) | NPC1RAB9AMITFPKMTDP1 | |
| SCHEMBL10044417 | 0.75 | NPC1 (0.62) | NPC1RAB9AMITFPKMTDP1 | |
| SCHEMBL9870217 | 0.75 | NPC1 (0.62) | NPC1RAB9AMITFPKMTDP1 | |
| SCHEMBL29703247 | 0.75 | TDP1 (0.72) | NPC1RAB9AMITFPKMTDP1 | |
| SCHEMBL7862743 | 0.75 | NPC1 (0.62) | NPC1RAB9AMITFPKMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5489592-A | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETES-RELATED DISORDERS | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1996-02-06 | — | — | US | claimed |
| US-20250340519-A1 | RADIOLABELLED COMPOUND | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-11-06 | — | — | US | disclosed |
| EP-4624459-A2 | RADIOLABELLED COMPOUND | Oxford University Innovation Limited (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-20210284613-A1 | RADIOLABELLED COMPOUND | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| US-20210284613-A1 | RADIOLABELLED COMPOUND | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| WO-2019186135-A1 | RADIOLABELLED COMPOUND | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-10-03 | — | — | WO | disclosed |
| US-5668279-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DIORDERS AND GASTROINTESTINAL DISORDERS | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0666851-A4 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS. | — | 1995-08-30 | — | — | EP | disclosed |
| EP-0666851-A1 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS | MERCK & CO. INC. (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994010151-A1 | SUBSTITUTED PHTHALAZINONES AS NEROTENSIN ANTAGONISTS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284613-A1 | RADIOLABELLED COMPOUND | PARP3, PARP2, PARP1 | NPC1 2451/4885RAB9A 1654/4885MITF 3979/4885 |
| US-20250340519-A1 | RADIOLABELLED COMPOUND | PARP3, PARP2, PARP1 | NPC1 2451/4885RAB9A 1654/4885MITF 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.